| Short Descr | Merkel cell carcinoma of lip |
| CMS-HCC v22 | 12 - Breast, Prostate, and Other Cancers and Tumors |
| CMS-HCC v24 | 12 - Breast, Prostate, and Other Cancers and Tumors |
| CMS-HCC v28 | 21 - Lymphoma and Other Cancers |
| ESRD-HCC v21 | 12 - Breast, Prostate, and Other Cancers and Tumors |
| ESRD-HCC v24 | 12 - Breast, Prostate, and Other Cancers and Tumors |
| HHS-HCC v07 | 12 - Breast (Age 50+) and Prostate Cancer, Benign/Uncertain Brain Tumors, and Other Cancers and Tumors |
| Rx-HCC v08 | 22 - Prostate, Breast, Bladder, and Other Cancers and Tumors |
| Home Health Clinical Group | MMTA_INFECT |
| Home Health Comorbidity Subgroup | Neoplasms 23 |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2015-10-01 | Added | Code established |
|
Code
|
Description
|
|---|---|
| A4641 | Radiopharmaceutical, diagnostic, not otherwise classified |
| A4648 | Tissue marker, implantable, any type, each |
| A4650 | Implantable radiation dosimeter, each |
| A9513 | Lutetium lu 177, dotatate, therapeutic, 1 millicurie |
| A9515 | Choline c-11, diagnostic, per study dose up to 20 millicuries |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries |
| A9574 | Air polymer-type a intrauterine foam, 0.1 ml |
| A9580 | Sodium fluoride f-18, diagnostic, per study dose, up to 30 millicuries |
| A9587 | Gallium ga-68, dotatate, diagnostic, 0.1 millicurie |
| A9588 | Fluciclovine f-18, diagnostic, 1 millicurie |
| A9593 | Gallium ga-68 psma-11, diagnostic, (ucsf), 1 millicurie |
| A9594 | Gallium ga-68 psma-11, diagnostic, (ucla), 1 millicurie |
| A9596 | Gallium ga-68 gozetotide, diagnostic, (illuccix), 1 millicurie |
| A9607 | Lutetium lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie |
| A9800 | Gallium ga-68 gozetotide, diagnostic, (locametz), 1 millicurie |
| C7503 | Open biopsy or excision of deep cervical node(s) with intraoperative identification (eg, mapping) of sentinel lymph node(s) including injection of non-radioactive dye when performed |
| C9067 | Gallium ga-68, dotatoc, diagnostic, 0.01 mci |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source [deleted] |
| G0010 | Administration of hepatitis b vaccine |
| G0027 | Semen analysis; presence and/or motility of sperm excluding huhner |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision |
| G0124 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician |
| G0141 | Screening cytopathology smears, cervical or vaginal, performed by automated system, with manual rescreening, requiring interpretation by physician |
| G0143 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with manual screening and rescreening by cytotechnologist under physician supervision |
| G0144 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system, under physician supervision |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision |
| G0147 | Screening cytopathology smears, cervical or vaginal, performed by automated system under physician supervision |
| G0148 | Screening cytopathology smears, cervical or vaginal, performed by automated system with manual rescreening |
| G0235 | Pet imaging, any site, not otherwise specified |
| G0339 | Image-guided robotic linear accelerator-based stereotactic radiosurgery, complete course of therapy in one session or first session of fractionated treatment |
| G0340 | Image-guided robotic linear accelerator-based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, second through fifth sessions, maximum five sessions per course of treatment |
| G0429 | Dermal filler injection(s) for the treatment of facial lipodystrophy syndrome (lds) (e.g., as a result of highly active antiretroviral therapy) |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source [deleted] |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source [deleted] |
| G2025 | Payment for a telehealth distant site service furnished by a rural health clinic (rhc) or federally qualified health center (fqhc) only |
| G6002 | Stereoscopic x-ray guidance for localization of target volume for the delivery of radiation therapy |
| G6003 | Radiation treatment delivery, single treatment area,single port or parallel opposed ports, simple blocks or no blocks: up to 5 mev |
| G6004 | Radiation treatment delivery, single treatment area,single port or parallel opposed ports, simple blocks or no blocks: 6-10 mev |
| G6005 | Radiation treatment delivery, single treatment area,single port or parallel opposed ports, simple blocks or no blocks: 11-19 mev |
| G6006 | Radiation treatment delivery, single treatment area,single port or parallel opposed ports, simple blocks or no blocks: 20 mev or greater |
| G6007 | Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks: up to 5 mev |
| G6008 | Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks: 6-10 mev |
| G6009 | Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks: 11-19 mev |
| G6010 | Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks: 20 mev or greater |
| G6011 | Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; up to 5 mev |
| G6012 | Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 mev |
| G6013 | Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev |
| G6014 | Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 20 mev or greater |
| G6015 | Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session |
| G6016 | Compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or more high resolution (milled or cast) compensator, convergent beam modulated fields, per treatment session |
| G6017 | Intra-fraction localization and tracking of target or patient motion during delivery of radiation therapy (eg,3d positional tracking, gating, 3d surface tracking), each fraction of treatment |
| G9147 | Outpatient intravenous insulin treatment (oivit) either pulsatile or continuous, by any means, guided by the results of measurements for: respiratory quotient; and/or, urine urea nitrogen (uun); and/or, arterial, venous or capillary glucose; and/or potassium concentration |
| J0640 | Injection, leucovorin calcium, per 50 mg |
| J0725 | Injection, chorionic gonadotropin, per 1,000 usp units |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) |
| J0882 | Injection, darbepoetin alfa, 1 microgram (for esrd on dialysis) |
| J0900 | Injection, testosterone enanthate and estradiol valerate, up to 1 cc [deleted] |
| J1000 | Injection, depo-estradiol cypionate, up to 5 mg |
| J1060 | Injection, testosterone cypionate and estradiol cypionate, up to 1 ml [deleted] |
| J1071 | Injection, testosterone cypionate, 1 mg |
| J1094 | Injection, dexamethasone acetate, 1 mg |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg |
| J1380 | Injection, estradiol valerate, up to 10 mg |
| J1410 | Injection, estrogen conjugated, per 25 mg |
| J1442 | Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram |
| J1447 | Injection, tbo-filgrastim, 1 microgram |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg |
| J1570 | Injection, ganciclovir sodium, 500 mg |
| J1620 | Injection, gonadorelin hydrochloride, per 100 mcg |
| J1815 | Injection, insulin, per 5 units |
| J1817 | Insulin for administration through dme (i.e., insulin pump) per 50 units |
| J2370 | Injection, phenylephrine hcl, up to 1 ml [deleted] |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg |
| J2675 | Injection, progesterone, per 50 mg |
| J2820 | Injection, sargramostim (gm-csf), 50 mcg |
| J3120 | Injection, testosterone enanthate, up to 100 mg [deleted] |
| J3121 | Injection, testosterone enanthate, 1 mg |
| J3130 | Injection, testosterone enanthate, up to 200 mg [deleted] |
| J3140 | Injection, testosterone suspension, up to 50 mg [deleted] |
| J3145 | Injection, testosterone undecanoate, 1 mg |
| J3150 | Injection, testosterone propionate, up to 100 mg [deleted] |
| J3355 | Injection, urofollitropin, 75 iu |
| J3485 | Injection, zidovudine, 10 mg |
| J7310 | Ganciclovir, 4.5 mg, long-acting implant |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg |
| J8510 | Busulfan; oral, 2 mg |
| J8515 | Cabergoline, oral, 0.25 mg |
| J8530 | Cyclophosphamide; oral, 25 mg |
| J8540 | Dexamethasone, oral, 0.25 mg |
| J8560 | Etoposide; oral, 50 mg |
| J8600 | Melphalan; oral, 2 mg |
| J8610 | Methotrexate; oral, 2.5 mg |
| J9000 | Injection, doxorubicin hydrochloride, 10 mg |
| J9001 | Injection, doxorubicin hydrochloride, all lipid formulations, 10 mg [deleted] |
| J9015 | Injection, aldesleukin, per single use vial |
| J9040 | Injection, bleomycin sulfate, 15 units |
| J9041 | Injection, bortezomib, 0.1 mg |
| J9042 | Injection, brentuximab vedotin, 1 mg |
| J9045 | Injection, carboplatin, 50 mg |
| J9046 | Injection, bortezomib (dr. reddy's), not therapeutically equivalent to j9041, 0.1 mg |
| J9048 | Injection, bortezomib (fresenius kabi), not therapeutically equivalent to j9041, 0.1 mg |
| J9049 | Injection, bortezomib (hospira), not therapeutically equivalent to j9041, 0.1 mg |
| J9050 | Injection, carmustine, 100 mg |
| J9060 | Injection, cisplatin, powder or solution, 10 mg |
| J9065 | Injection, cladribine, per 1 mg |
| J9070 | Cyclophosphamide, 100 mg [deleted] |
| J9098 | Injection, cytarabine liposome, 10 mg |
| J9100 | Injection, cytarabine, 100 mg |
| J9120 | Injection, dactinomycin, 0.5 mg |
| J9130 | Dacarbazine, 100 mg |
| J9150 | Injection, daunorubicin, 10 mg |
| J9151 | Injection, daunorubicin citrate, liposomal formulation, 10 mg |
| J9165 | Injection, diethylstilbestrol diphosphate, 250 mg |
| J9171 | Injection, docetaxel, 1 mg |
| J9181 | Injection, etoposide, 10 mg |
| J9185 | Injection, fludarabine phosphate, 50 mg |
| J9190 | Injection, fluorouracil, 500 mg |
| J9200 | Injection, floxuridine, 500 mg |
| J9202 | Goserelin acetate implant, per 3.6 mg |
| J9206 | Injection, irinotecan, 20 mg |
| J9208 | Injection, ifosfamide, 1 gram |
| J9213 | Injection, interferon, alfa-2a, recombinant, 3 million units |
| J9214 | Injection, interferon, alfa-2b, recombinant, 1 million units |
| J9215 | Injection, interferon, alfa-n3, (human leukocyte derived), 250,000 iu |
| J9218 | Leuprolide acetate, per 1 mg |
| J9230 | Injection, mechlorethamine hydrochloride, (nitrogen mustard), 10 mg |
| J9245 | Injection, melphalan hydrochloride, not otherwise specified, 50 mg |
| J9250 | Methotrexate sodium, 5 mg [deleted] |
| J9260 | Injection, methotrexate sodium, 50 mg |
| J9263 | Injection, oxaliplatin, 0.5 mg |
| J9265 | Injection, paclitaxel, 30 mg [deleted] |
| J9267 | Injection, paclitaxel, 1 mg |
| J9270 | Injection, plicamycin, 2.5 mg |
| J9280 | Injection, mitomycin, 5 mg |
| J9293 | Injection, mitoxantrone hydrochloride, per 5 mg |
| J9340 | Injection, thiotepa, 15 mg |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg |
| J9360 | Injection, vinblastine sulfate, 1 mg |
| J9370 | Vincristine sulfate, 1 mg |
| J9390 | Injection, vinorelbine tartrate, 10 mg |
| L8000 | Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type |
| L8001 | Breast prosthesis, mastectomy bra, with integrated breast prosthesis form, unilateral, any size, any type |
| L8002 | Breast prosthesis, mastectomy bra, with integrated breast prosthesis form, bilateral, any size, any type |
| L8010 | Breast prosthesis, mastectomy sleeve |
| L8015 | External breast prosthesis garment, with mastectomy form, post mastectomy |
| L8020 | Breast prosthesis, mastectomy form |
| L8030 | Breast prosthesis, silicone or equal, without integral adhesive |
| L8031 | Breast prosthesis, silicone or equal, with integral adhesive |
| L8032 | Nipple prosthesis, prefabricated, reusable, any type, each |
| L8033 | Nipple prosthesis, custom fabricated, reusable, any material, any type, each |
| L8035 | Custom breast prosthesis, post mastectomy, molded to patient model |
| L8039 | Breast prosthesis, not otherwise specified |
| L8040 | Nasal prosthesis, provided by a non-physician |
| L8041 | Midfacial prosthesis, provided by a non-physician |
| L8042 | Orbital prosthesis, provided by a non-physician |
| L8043 | Upper facial prosthesis, provided by a non-physician |
| L8044 | Hemi-facial prosthesis, provided by a non-physician |
| L8045 | Auricular prosthesis, provided by a non-physician |
| L8046 | Partial facial prosthesis, provided by a non-physician |
| L8047 | Nasal septal prosthesis, provided by a non-physician |
| L8048 | Unspecified maxillofacial prosthesis, by report, provided by a non-physician |
| L8049 | Repair or modification of maxillofacial prosthesis, labor component, 15 minute increments, provided by a non-physician |
| L8600 | Implantable breast prosthesis, silicone or equal |
| L8603 | Injectable bulking agent, collagen implant, urinary tract, 2.5 ml syringe, includes shipping and necessary supplies |
| L8610 | Ocular implant |
| P3000 | Screening papanicolaou smear, cervical or vaginal, up to three smears, by technician under physician supervision |
| P3001 | Screening papanicolaou smear, cervical or vaginal, up to three smears, requiring interpretation by physician |
| Q0083 | Chemotherapy administration by other than infusion technique only (e.g., subcutaneous, intramuscular, push), per visit |
| Q0084 | Chemotherapy administration by infusion technique only, per visit |
| Q0085 | Chemotherapy administration by both infusion technique and other technique(s) (e.g., subcutaneous, intramuscular, push), per visit |
| Q0115 | Post-coital direct, qualitative examinations of vaginal or cervical mucous |
| Q2017 | Injection, teniposide, 50 mg |
| Q2026 | Injection, radiesse, 0.1 ml |
| Q2028 | Injection, sculptra, 0.5 mg |
| Q2050 | Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg |
| Q3031 | Collagen skin test |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg |
| Q5110 | Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg |
| Q5120 | Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg |
| Q5125 | Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram |
| Q5127 | Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg |
| Q5130 | Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg |
| Q9951 | Low osmolar contrast material, 400 or greater mg/ml iodine concentration, per ml |
| Q9958 | High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml |
| Q9959 | High osmolar contrast material, 150-199 mg/ml iodine concentration, per ml |
| Q9960 | High osmolar contrast material, 200-249 mg/ml iodine concentration, per ml |
| Q9961 | High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml |
| Q9962 | High osmolar contrast material, 300-349 mg/ml iodine concentration, per ml |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml |
| Q9964 | High osmolar contrast material, 400 or greater mg/ml iodine concentration, per ml |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
| S0122 | Injection, menotropins, 75 iu |
| S0126 | Injection, follitropin alfa, 75 iu |
| S0128 | Injection, follitropin beta, 75 iu |
| S0132 | Injection, ganirelix acetate, 250 mcg |
| S0145 | Injection, pegylated interferon alfa-2a, 180 mcg per ml |
| S0148 | Injection, pegylated interferon alfa-2b, 10 mcg |
| S0187 | Tamoxifen citrate, oral, 10 mg |
| S0265 | Genetic counseling, under physician supervision, each 15 minutes |
| S2078 | LAPAROSCOPIC SUPRACERVICAL HYSTERECTOMY (SUBTOTAL HYSTERECTOMY), WITH OR WITHOUT REMOVAL OF TUBE(S), WITH OR WITHOUT REMOVAL OF OVARY(S) [deleted] |
| S2140 | Cord blood harvesting for transplantation, allogeneic |
| S2142 | Cord blood-derived stem-cell transplantation, allogeneic |
| S2150 | Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre-and post-transplant care in the global definition |
| S4011 | In vitro fertilization; including but not limited to identification and incubation of mature oocytes, fertilization with sperm, incubation of embryo(s), and subsequent visualization for determination of development |
| S4013 | Complete cycle, gamete intrafallopian transfer (gift), case rate |
| S4014 | Complete cycle, zygote intrafallopian transfer (zift), case rate |
| S4015 | Complete in vitro fertilization cycle, not otherwise specified, case rate |
| S4016 | Frozen in vitro fertilization cycle, case rate |
| S4017 | Incomplete cycle, treatment cancelled prior to stimulation, case rate |
| S4018 | Frozen embryo transfer procedure cancelled before transfer, case rate |
| S4020 | In vitro fertilization procedure cancelled before aspiration, case rate |
| S4021 | In vitro fertilization procedure cancelled after aspiration, case rate |
| S4022 | Assisted oocyte fertilization, case rate |
| S4023 | Donor egg cycle, incomplete, case rate |
| S4025 | Donor services for in vitro fertilization (sperm or embryo), case rate |
| S4026 | Procurement of donor sperm from sperm bank |
| S4028 | Microsurgical epididymal sperm aspiration (mesa) |
| S4035 | Stimulated intrauterine insemination (iui), case rate |
| S4037 | Cryopreserved embryo transfer, case rate |
| S4993 | Contraceptive pills for birth control |
| S5550 | Insulin, rapid onset, 5 units |
| S5551 | Insulin, most rapid onset (lispro or aspart); 5 units |
| S5552 | Insulin, intermediate acting (nph or lente); 5 units |
| S5553 | Insulin, long acting; 5 units |
| S5560 | Insulin delivery device, reusable pen; 1.5 ml size |
| S5561 | Insulin delivery device, reusable pen; 3 ml size |
| S5565 | Insulin cartridge for use in insulin delivery device other than pump; 150 units |
| S5566 | Insulin cartridge for use in insulin delivery device other than pump; 300 units |
| S5570 | Insulin delivery device, disposable pen (including insulin); 1.5 ml size |
| S5571 | Insulin delivery device, disposable pen (including insulin); 3 ml size |
| S9537 | Home therapy; hematopoietic hormone injection therapy (e.g., erythropoietin, g-csf, gm-csf); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem |
| S9560 | Home injectable therapy; hormonal therapy (e.g.; leuprolide, goserelin), including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem |
| V2623 | Prosthetic eye, plastic, custom |
| V2624 | Polishing/resurfacing of ocular prosthesis |
| V2625 | Enlargement of ocular prosthesis |
| V2626 | Reduction of ocular prosthesis |
| V2627 | Scleral cover shell |
| V2628 | Fabrication and fitting of ocular conformer |
| V2629 | Prosthetic eye, other type |
| No matching codes found | |
|
Code
|
Description
|
|---|---|
| 209.31 | Merkel cell carcinoma of the face |
| No matching codes found | |